Ongoing disruption of RSV epidemiology in children in Switzerland.

Autor: Meyer Sauteur PM; Division of Infectious Diseases and Hospital Epidemiology, Children's Research Center, University Children's Hospital Zurich, University of Zurich, Zurich, Switzerland., Plebani M; Pediatric Infectious Diseases and Vaccinology Unit, Department Women-Mother-Child, Lausanne University Hospital, Lausanne, Switzerland., Trück J; Divisions of Allergy and Immunology, Children's Research Center, University Children's Hospital Zurich, University of Zurich, Zurich, Switzerland., Wagner N; Pediatric Infectious Diseases Unit, Division of General Pediatrics, Department of Woman, Child, and Adolescent Medicine, Geneva University Hospitals, Geneva, Switzerland., Agyeman PKA; Division of Pediatric Infectious Disease, Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Switzerland.
Jazyk: angličtina
Zdroj: The Lancet regional health. Europe [Lancet Reg Health Eur] 2024 Sep 02; Vol. 45, pp. 101050. Date of Electronic Publication: 2024 Sep 02 (Print Publication: 2024).
DOI: 10.1016/j.lanepe.2024.101050
Abstrakt: Competing Interests: PMMS, JT and PKAA have participated in advisory board meetings for Nirsevimab organised by Sanofi. JT has received speaker fees from Sanofi and is member of a data safety monitoring board for mRNA-based RSV vaccines by Moderna.
Databáze: MEDLINE